
jan pm et
summari develop manufactur market medic devic intervent medic
specialti three segment cardiovascular rhythm manag medsurg
price-to-earnings oper ep
risk assess reflect compani stabl
oper within competit area health care
industri high growth prospect howev
moder level debt net debt total capit
june bsx
continu success depend abil continu
innov commerci new innov --
easi task
feb ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
oct stock trade
expect sale grow
follow growth
made mani tuck-in acquisit
strengthen core busi enabl
close acquisit claret
medic veniti augmenix
one anticip product
replac tavr experienc delay
 eu launch date origin date
sometim
present opportun primari
tavr competitor
captur market
share time still
market acur tavr market
share loss concern may overst
lotu edg current pend fda approv
expect launch europ
see adjust oper margin
still far ambiti
target margin yet
quit success expand margin
far commit deliv bp
margin improv
think trade
ep estim attract
valu februari recal lotu
valv heart devic europ remov
devic clinic trial us said
problem would rectifi quickli
expect devic back european
market delay origin
expect pleas see
mani product
pipelin aid recent tuck-in acquisit
nvision medic ovarian cancer
treatment nxthera enlarg prostat
treatment optimist continu
 spend rang think
diversifi portfolio product
make top supplier hospit also
think could take-over target
risk target price recommend
pressur weak execut new product
target price base
above-p ep
estim numer product
launch robust pipelin like
grow faster peer
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview develop market minim invas medic devic
use broad rang intervent medic specialti offer product sale
seven core categori intervent cardiolog sale cardiac rhythm manag
endoscopi peripher intervent urolog pelvic health neuromodul
electrophysiolog seven core categori group three report segment
cardiovascular rhythm manag medsurg
cardiovascular segment includ intervent cardiolog peripher intervent
intervent cardiolog busi develop manufactur technolog diagnos treat
coronari arteri diseas cardiovascular disord includ structur heart condit product
includ drug-elut coronari stent system broad line product offer treat atherosclerosi
princip caus coronari arteri obstruct diseas devic structur heart therapi
watchman appendag closur acur aortic valv system brand peripher intervent
busi develop manufactur product diagnos treat peripher arteri diseas includ
broad line medic devic use percutan translumin angioplasti pta peripher
vascular diseas well product diagnos treat eas variou form cancer product
offer includ product stent balloon cathet wire atherectomi peripher
rhythm manag segment includ cardiac rhythm manag electrophysiolog
busi develop manufactur varieti implant devic monitor heart
deliv electr treat cardiac abnorm implant cardiovert defibril
pacemak current gener defibril reson famili devic avail
major market around world electrophysiolog busi develop manufactur
less-invas medic technolog use diagnosi treatment rate rhythm disord
heart includ broad portfolio therapeut diagnost cathet varieti equip
use electrophysiolog lab
medsurg segment includ endoscopi urolog pelvic health neuromodul
endoscopi busi develop manufactur devic diagnos treat broad rang
gastrointestin gi pulmonari condit innov less invas technolog urolog
pelvic health busi develop manufactur devic treat variou urolog pelvic condit
male femal anatomi includ kidney stone benign prostat hyperplasia bph erectil
dysfunct male incontin pelvic floor disord abnorm uterin bleed uterin fibroid
polyp neuromodul busi develop manufactur devic treat variou neurolog
movement disord manag chronic pain
competit landscap face signific competit across product line market
primari competitor includ plc cook medic well wide rang
medic devic compani sell singl limit number competit product particip
specif market segment like mani medic devic compani also face competit
non-med devic compani pharmaceut compani may offer altern therapi
diseas state could also treat use product
financi trend revenu grew billion compani five-year cumul
annual growth rate compound-annual-growth-rate revenu meanwhil five-year compound-annual-growth-rate adjust ep
adjust ep vs spend larg amount research
develop year end decemb spent million
revenu march net debt total capit billion
think manag given cash flow oper billion
oper
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
neutral sinc januari technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
posit continu expect
compani sub-industri grow
posit macro environ addit
sub-industri mani product area
histor recession-resist
particularli equip use non-elect
procedur valuat continu high
industri driven expand margin
robust revenu growth compani
industri think lax food
drug administr fda
increas capabl technolog
enabl medic devic manufactur bring
innov product market faster
constant currenc basi expect
revenu sub-industri rise
high-single-digit low-double-digit
percentag driven continu pipelin
innov new product emerg market
expans speed new product
come market increas recent
year success effort
fda reduc approv time medic
devic time see price
pressur incess head wind medic
impact trade war appear mild
far medic equip compani
accord medic devic trade
septemb retaliatori tariff
billion us medic technolog export
although us chines govern
seek lower health care cost provid
equip manufactur insul
industri earlier commentari
medic devic manufactur suggest
impact trade war would manag
provid commentari impact
trade war earn
on-going threat state health
care system current us
administr continu attempt repeal
afford act stop
multipl time gather suffici
number vote pass variou repeal
replac bill recent on-going
lawsuit texa question
constitution
think import watch
mid-term elect novemb
health care appear import topic
hospit spend larg driver medic
equip sale robust
strong us economi
tax cut job act tcja individu
mandat roll think
hospit could see pressur lead
sale pressur medic equip
requir american health
insur without requir
expect lower number american
gener see posit long-term
fundament includ increas global
demand qualiti health care age
popul rise outlay lead
steadi flow innov product
 health equip
sub-index increas vs rise
 composit index year
date septemb
increas composit
base index
five-year market price perform jan
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
strong buy buy day ago unconfirm
report stryker corpor approach
acquisit deni discuss regard potenti
acquisit howev disput approach think
still possibl deal given robust pipelin continu view
pipelin favor mani promis avenu growth much
near-term stock perform may hing success approv launch
lotu edg transcathet aortic valv replac think
success execut next step /kevin huang cfa
scientif corpor accord unconfirm report
includ wall street journal stryker corpor made
take-over approach potenti creat diversifi medic devic
titan combin annual sale billion rais target price
see sale synergi well cost save synergi
expertis orthoped neurotechnolog spine expertis
cardiovascular rhythm manag compani expertis
medic surgeri prolif acquir complet numer
acquisit past sever year would largest deal
complet /kevin huang cfa
scientif rais price target
in-lin peer forward ep estim ep
vs higher estim see ep estim
sale grew billion almost
half growth come benefici currenc movement organ basi
sale grew medsurg grow rhythm manag
cardiovascular encourag broad-bas momentum across
geograph region product line addit bsx healthi
pipelin includ sever recent tuck-in acquisit rais
guidanc organ sale growth rang
commentari around launch time lotu edg transcathet aortic
valv replac tavr platform remain unchang product track
launch european market /kevin huang
analyst research note compani news
pm et cfra lower opinion share buy
strong buy rais target
above-p ep estim continu
favor view ew leadership posit structur heart therapi market
expect market rapidli expand upon present data
trial march expect posit ew share
ew trade approxim morn news settlement
ew agre pay million settl
long-stand patent disput europ part
settlement compani agre litig disput relat
transcathet aortic valv certain mitral valv repair devic left
atrial appendag closur devic view posit
compani clear air enabl two medic devic
manufactur focu effort capit rapidli grow
et cfra reiter strong buy opinion share boston
scientif corpor maintain target
ep estim multipl exce
five-year rang see strong potenti compani promis
product portfolio posit expand market ep
vs equal estim lower ep
foreign currenc benefici initi expect sale
increas organ billion organ medsurg
segment grew rhythm neuro cardiovascular
increas guidanc structur heart busi strength
product watchman left atrial appendag closur devic acur tavr
look toward expect eluvia drug-elut stent lotu edg
tavr import growth driver eluvia receiv fda approv
septemb earli stage launch lotu edg
expect launch europ /kevin
scientif corpor lift target
above-p ep estim
valu higher forward multipl increas convict
futur growth opportun encapsul promis product
expand market promis expect product
launch eluvia drug-elut stent lotu edg transcathet
aortic valv replac tavr devic present posit data
eluvia septemb transcathet cardiovascular therapeut tct
confer eluvia receiv fda approv market septemb
also high expect lotu edg tavr
delay submit fda approv mid-august /kevin huang cfa
scientif maintain target
above-p ep estim multipl
high-end bsx five-year rang
strong recent pipelin product portfolio ep vs
higher estim rais ep
ep sale increas
organ billion organ medsurg segment grew
rhythm neuro cardiovascular still updat
develop progress lotu edg transcathet aortic valv
replac tavr manag reiter next updat would
file final technic modul longer
proceed program hand acur tavr platform
proceed ahead plan invest global expans expect
launch next gener acur tavr europ
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
